<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01036165</url>
  </required_header>
  <id_info>
    <org_study_id>29652</org_study_id>
    <nct_id>NCT01036165</nct_id>
  </id_info>
  <brief_title>A Multicenter, Open-label, RebiSmart™ Autoinjector Ease of Use Study</brief_title>
  <acronym>Performs</acronym>
  <official_title>A Twelve-week, Phase IIIb, Open-label, Single-arm, Multicenter Trial to Evaluate Ease of Use of an Electronic Autoinjector (RebiSmart™) for Self-injection in Subjects With Relapsing Multiple Sclerosis (RMS) Treated With Rebif® 44mcg Subcutaneously (sc) Three Times a Week (Tiw)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMD Serono</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EMD Serono</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the RebiSmart™ for

        -  ease of use

        -  multiple domains related to subject's acceptability and satisfaction

        -  reliability of the correct function for self-injection of Rebif® 44 mcg sc tiw in
           subjects with RMS.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Primary Endpoint is the Proportion of RMS Subjects Rating the RebiSmart™ Autoinjector as 'Easy to Use' or 'Very Easy to Use' for Self-injection in a User Trial Questionnaire.</measure>
    <time_frame>at 12 Weeks</time_frame>
    <description>Data from the User Trial Questionnaire-B, Question 13 (Overall, how do you rate your experience with using the injection device). Mean and confidence intervals refer to proportion of subjects responding positively to question. Missing values were replaced with worst case response.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Multiple Secondary Endpoints Will be Assessed, Based on Questions From the User Trial Questionnaire Related to the RebiSmart™ Autoinjector Use-related Outcomes.</measure>
    <time_frame>at Week 12</time_frame>
    <description>The User Trial Questionnaire B was administered at Week 6 and Week 12 to assess the ease of use, functional reliability, overall satisfaction, satisfaction with device attributes, convenience, safety and portability of the Rebismart. Means and confidence intervals refer to the proportion of subjects responding positively, based on the number of non-missing values for each question. Secondary endpoints presented for decriptive purposes only thus no statistical analysis performed.</description>
  </secondary_outcome>
  <enrollment type="Actual">103</enrollment>
  <condition>Multiple Sclerosis</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RebiSmart™</intervention_name>
    <description>The RebiSmart™ autoinjector contains Rebif® 132 mcg multidose cartridges for sc injection.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female subjects, 18-65 years of age, inclusive, at the time of informed
             consent signature

          2. RMS diagnosed according to the McDonald criteria

          3. Currently receiving Rebif® 44mcg sc tiw using manual injections and/or Rebiject II
             autoinjector for greater than or equal to twelve weeks

          4. Capable of self-injecting using the RebiSmart™ autoinjector. Self- injecting is
             defined as being able to make 2 of the 3 weekly injections without assistance.

          5. Be willing and able to comply with the study procedures for the duration of the trial

          6. Have given written informed consent and signed Health Insurance Portability and
             Accountability Act (HIPAA) Authorization before any study- related activities are
             carried out

          7. Female subjects must not be either pregnant or breast-feeding and must lack
             childbearing potential, as defined by either:

               -  Being post-menopausal or surgically sterile, or using a highly effective method
                  of contraception (defined as a method that results in a low failure rate (i.e.
                  less than 1% per year) when used consistently and correctly, and includes for
                  instance, implants, injectables, combined oral contraceptives*, some intrauterine
                  devices, sexual abstinence or vasectomised partner)

               -  Female subjects of childbearing potential must have a negative pregnancy test at
                  Screening and Study Day 1 to be included in the trial. A urine pregnancy test
                  will also be done at the Week 12/Exit visit

                    -  Note for subjects using a hormonal contraceptive method: No formal drug
                       interaction studies have been carried out with Rebif®. As interferons have
                       been reported to exert an inhibitory activity on hepatic microsomal enzymes,
                       it is unlikely that the clearance of oral contraceptives would increase and
                       result in decreased efficacy. In over 10,000 patient years of clinical trial
                       experience with Rebif®, there has never been any indication of an
                       interaction with oral contraceptives.

        Exclusion Criteria:

          1. Have used any other injectable medications (e.g. for pain) on a regular basis during
             the week prior to Screening or throughout the duration of the trial (the
             administration of a single injection for treatment or prophylaxis of a condition
             unrelated to MS or Rebif® therapy (e.g., influenza or pneumococcus vaccination) will
             be acceptable)

          2. Have received MS therapy other than Rebif® within twelve weeks prior to Screening or
             at any time during the trial (e.g., other disease modifying drugs, Rebif® New
             Formulation, combination therapy, immunomodulatory and/or immunosuppressive agents,
             including but not limited to any other interferon (Avonex/Betaseron/Extavia),
             glatiramer acetate (Copolymer I), cyclophosphamide, cyclosporine, methotrexate,
             linomide, azathioprine, mitoxantrone, teriflunomide, laquinimod, cladribine,
             fingolimod (FTY720), total lymphoid irradiation, anti-lymphocyte monoclonal antibody
             treatment (e.g. natalizumab, alemtuzumab/Campath, anti-CD4), Intravenous
             immunoglobulin (IVIg), cytokines or anti-cytokine therapy) and telbivudine

          3. Have inadequate liver function, defined by a alanine aminotransferase (ALT) &gt; 2.5x
             upper limit of normal (ULN), or alkaline phosphatase &gt; 2.5x ULN, or total bilirubin &gt;
             2.5x ULN

          4. Have inadequate bone marrow reserve, defined as a total white blood cell count &lt; 3.0x
             109/L, platelet count &lt; 75x109/L, hemoglobin &lt; 100g/L

          5. Have complete transverse myelitis or simultaneous-onset bilateral optic neuritis

          6. Have a history of alcohol or drug abuse

          7. Have thyroid dysfunction

          8. Have moderate to severe renal impairment

          9. Have a major medical or psychiatric illness that in the opinion of the investigator
             creates undue risk to the subject or could affect compliance with the study protocol

         10. Have a history of seizures not adequately controlled by treatment

         11. Have serious or acute cardiac disease, such as uncontrolled dysrhythmias, uncontrolled
             angina pectoris, cardiomyopathy, or uncontrolled congestive heart failure

         12. Have, in the opinion of the investigator, major visual, physical or cognitive
             impairment that would preclude the subject from self-injecting with the RebiSmart™
             autoinjector

         13. Have a known hypersensitivity or allergy to interferon-beta or any of the excipients

         14. Have participated in another clinical trial within the past thirty days

         15. Are pregnant or attempting to conceive

         16. Have previously used a RebiSmart™ autoinjector
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fernando Dangond, MD</last_name>
    <role>Study Director</role>
    <affiliation>EMD Serono</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>EMD Serono, Inc.</name>
      <address>
        <city>Rockland</city>
        <state>Massachusetts</state>
        <zip>02370</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2009</study_first_submitted>
  <study_first_submitted_qc>December 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2009</study_first_posted>
  <results_first_submitted>November 30, 2010</results_first_submitted>
  <results_first_submitted_qc>November 30, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 22, 2010</results_first_posted>
  <last_update_submitted>August 2, 2013</last_update_submitted>
  <last_update_submitted_qc>August 2, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 8, 2013</last_update_posted>
  <responsible_party>
    <name_title>Ahmad Al-Sabbagh, Vice President Medical Affairs Neurology</name_title>
    <organization>EMD Serono, Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>103 subjects were recruited from 15 US clinics in the US during the trial period February 2010 to August 2010</recruitment_details>
      <pre_assignment_details>Subjects who signed informed consent and satisfied the eligibility critera at screening returned to the clinic on study day 1 to begin treatment with the Rebismart autoinjector. All subjects participating in the trial received Rebif 44 mcg sc tiw using the Rebismart autoinjector for 12 weeks.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Subject Disposition</title>
          <description>Intent-to-Treat Analysis</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="103"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="88"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Device Related Issues</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Problems finding proper area to inject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Subject Disposition</title>
          <description>Intent-to-Treat Analysis</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="103"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.4" spread="9.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Primary Endpoint is the Proportion of RMS Subjects Rating the RebiSmart™ Autoinjector as ‘Easy to Use’ or ‘Very Easy to Use’ for Self-injection in a User Trial Questionnaire.</title>
        <description>Data from the User Trial Questionnaire-B, Question 13 (Overall, how do you rate your experience with using the injection device). Mean and confidence intervals refer to proportion of subjects responding positively to question. Missing values were replaced with worst case response.</description>
        <time_frame>at 12 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Subject Disposition</title>
            <description>Intent-to-Treat Analysis</description>
          </group>
        </group_list>
        <measure>
          <title>The Primary Endpoint is the Proportion of RMS Subjects Rating the RebiSmart™ Autoinjector as ‘Easy to Use’ or ‘Very Easy to Use’ for Self-injection in a User Trial Questionnaire.</title>
          <description>Data from the User Trial Questionnaire-B, Question 13 (Overall, how do you rate your experience with using the injection device). Mean and confidence intervals refer to proportion of subjects responding positively to question. Missing values were replaced with worst case response.</description>
          <units>Proportion of subjects</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.78" lower_limit="0.70" upper_limit="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean positive response</param_type>
            <param_value>0.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>0.86</ci_upper_limit>
            <estimate_desc>Confidence Interval calculated from normal approximation to the binomial. The primary objective was met if the lower limit of the 95% confidence interval was &gt;0.50.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Multiple Secondary Endpoints Will be Assessed, Based on Questions From the User Trial Questionnaire Related to the RebiSmart™ Autoinjector Use-related Outcomes.</title>
        <description>The User Trial Questionnaire B was administered at Week 6 and Week 12 to assess the ease of use, functional reliability, overall satisfaction, satisfaction with device attributes, convenience, safety and portability of the Rebismart. Means and confidence intervals refer to the proportion of subjects responding positively, based on the number of non-missing values for each question. Secondary endpoints presented for decriptive purposes only thus no statistical analysis performed.</description>
        <time_frame>at Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Subject Disposition</title>
            <description>Intent-to-Treat Analysis</description>
          </group>
        </group_list>
        <measure>
          <title>Multiple Secondary Endpoints Will be Assessed, Based on Questions From the User Trial Questionnaire Related to the RebiSmart™ Autoinjector Use-related Outcomes.</title>
          <description>The User Trial Questionnaire B was administered at Week 6 and Week 12 to assess the ease of use, functional reliability, overall satisfaction, satisfaction with device attributes, convenience, safety and portability of the Rebismart. Means and confidence intervals refer to the proportion of subjects responding positively, based on the number of non-missing values for each question. Secondary endpoints presented for decriptive purposes only thus no statistical analysis performed.</description>
          <units>Percentage of subjects</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Device makes injections simple</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.8" lower_limit="73.8" upper_limit="89.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Allows easy access to skin injection sites</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.5" lower_limit="71.1" upper_limit="88.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Helps me self-administer Injections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.1" lower_limit="76.4" upper_limit="91.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Step by step Instructions are a key benefit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.2" lower_limit="87.9" upper_limit="98.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ease of using injection device</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.9" lower_limit="84.9" upper_limit="96.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ease of loading cartridge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.7" lower_limit="94.6" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ease of inserting the needle</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.1" lower_limit="76.4" upper_limit="91.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ease of pushing the button</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.6" lower_limit="92.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ease of holding device during injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.1" lower_limit="76.4" upper_limit="91.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ease of removing the needle from device</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.1" lower_limit="67.2" upper_limit="85.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Able to often or always administer full injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.9" lower_limit="96.6" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rate the convenience of the device</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.5" lower_limit="80.6" upper_limit="94.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Subject Disposition</title>
          <description>Intent-to-Treat Analysis</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title vocab="Medra 13.0">Nephrolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>Medra 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="92" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (13.0)">Injection site erythema</sub_title>
                <counts group_id="E1" events="35" subjects_affected="35" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Injection site haematoma</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Injection Site Pain</sub_title>
                <counts group_id="E1" events="52" subjects_affected="52" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Injection site haemorrhage</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Multiple Sclerosis relapse</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Neither Institution nor any Principal Investigators shall publish or present any results from such Study to any third parties until: (i) EMD Serono publishes the results from all sites participating in such Study; (ii) Institution receives notification from EMD Serono that publication of the multi-site results is no longer planned; or (iii) twenty-four (24) months following the completion of the multi-site study at all sites, whichever occurs first.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Fernando Dangond, MD</name_or_title>
      <organization>EMD Serono, Inc.</organization>
      <phone>781-681-2348</phone>
      <email>Fernando.dangond@emdserono.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

